Activity and Safety of Front-linevenetoclax and Rituximab Association (VeRiTAs) in Young and Fit Patients With Chronic Lymphocytic Leukemia (CLL) and Umutated IGVH and/or Disrupted TP53. A Phase 2 Multicenter Study
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2018
Price : $35 *
At a glance
- Drugs Rituximab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms VeRitAs
- 19 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Nov 2018.
- 31 Aug 2018 Biomarkers information updated
- 03 Aug 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.